Cargando…
Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome
Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years. However, immunophenotypic characterization of these cancer stem cells remains sparse. In acute myeloid leukaemia (AML), we have previously described aberrant expression of the C‐type le...
Autores principales: | Toft‐Petersen, Marie, Nederby, Line, Kjeldsen, Eigil, Kerndrup, Gitte B., Brown, Gordon D., Hokland, Peter, Stidsholt Roug, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091626/ https://www.ncbi.nlm.nih.gov/pubmed/27612176 http://dx.doi.org/10.1111/bjh.14270 |
Ejemplares similares
-
A novel del(8)(q23.2q24.11) contributing to disease progression in a case of JAK2/TET2 double mutated chronic myelomonocytic leukemia
por: Toft-Petersen, Marie, et al.
Publicado: (2014) -
Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A‐related cancer stem cell biology
por: Bill, Marie, et al.
Publicado: (2018) -
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017) -
Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
por: Xu, Jinglan, et al.
Publicado: (2008) -
Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta‐analysis
por: Park, Sophie, et al.
Publicado: (2016)